New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
ApexOnco Front Page
Recent articles
The project has priority review, but deaths could raise eyebrows.
The deal for ISB 2001 is worth $700m up front.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
ESO-T01 delivers its first four multiple myeloma case reports.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
